Lishi Lin

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 10

Top Topics

Mechanical Ventilation

Bariatric Surgery

Epidermal Growth Factor Receptor

Top Venues

Cancer chemotherapy and pharmacology

Cancer medicine

Therapeutic drug monitoring

Clinical and translational science

This page only lists publications with an associated author ORCID identifier.

Publications

Lishi Lin, Aletta P I Houwink, Jolanda M van Dieren, Esther K Wolthuis, Johannes V van Thienen, Michiel S van der Heijden, John B A G Haanen, Jos H Beijnen, Alwin D R Huitema
Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune-related adverse events of immune checkpoint inhibitors. Cancer medicine 13 (12) (2024)
Cedric Lau, Ma Ida Mohmaed Ali, Lishi Lin, Dorieke E M van Balen, Bart A W Jacobs, Bastiaan Nuijen, Robert M Smeenk, Neeltje Steeghs, Alwin D R Huitema
Impact of bariatric surgery on oral anticancer drugs: an analysis of real-world data. Cancer chemotherapy and pharmacology 94 (1) (2024)
Cedric Lau, Ma Ida Mohmaed Ali, Lishi Lin, Dorieke E M van Balen, Bart A W Jacobs, Bastiaan Nuijen, Robert M Smeenk, Neeltje Steeghs, Alwin D R Huitema
Impact of bariatric surgery on oral anticancer drugs: an analysis of real-world data. Cancer chemotherapy and pharmacology (2024)
Lishi Lin, Aletta P I Houwink, Jolanda M van Dieren, Esther K Wolthuis, Johannes V van Thienen, Michiel S van der Heijden, John B A G Haanen, Jos H Beijnen, Alwin D R Huitema
Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune-related adverse events of immune checkpoint inhibitors. Cancer medicine 13 (12) (2024)
Lishi Lin, Aletta P I Houwink, Jolanda M van Dieren, Esther K Wolthuis, Johannes V van Thienen, Michiel S van der Heijden, John B A G Haanen, Jos H Beijnen, Alwin D R Huitema
Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune-related adverse events of immune checkpoint inhibitors. Cancer medicine 13 (12) (2024)
Cedric Lau, Ma Ida Mohmaed Ali, Lishi Lin, Dorieke E M van Balen, Bart A W Jacobs, Bastiaan Nuijen, Robert M Smeenk, Neeltje Steeghs, Alwin D R Huitema
Impact of bariatric surgery on oral anticancer drugs: an analysis of real-world data. Cancer chemotherapy and pharmacology 94 (1) (2024)
Cedric Lau, Ma Ida Mohmaed Ali, Lishi Lin, Dorieke E M van Balen, Bart A W Jacobs, Bastiaan Nuijen, Robert M Smeenk, Neeltje Steeghs, Alwin D R Huitema
Impact of bariatric surgery on oral anticancer drugs: an analysis of real-world data. Cancer chemotherapy and pharmacology 94 (1) (2024)
Lishi Lin, Hannerieke J Barkman, Egbert F Smit, Adrianus J de Langen, Neeltje Steeghs, Jos H Beijnen, Alwin D R Huitema
Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients. Therapeutic drug monitoring (2023)
Julie M Janssen, Remy B Verheijen, Tirsa T van Duijl, Lishi Lin, Michel M van den Heuvel, Jos H Beijnen, Neeltje Steeghs, Daan van den Broek, Alwin D R Huitema, Thomas P C Dorlo
Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR-mutant non-small cell lung cancer. Clinical and translational science 15 (8) (2022)
Lishi Lin, Egbert F Smit, Adrianus J de Langen, Dorieke E M van Balen, Jos H Beijnen, Alwin D R Huitema
Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice. Targeted oncology (2021)